-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) call put ratio 1 call to 3.3 puts with a focus on December 95 and 100 puts as share price down 8%
-
-
-
-
-
-
-
Kymera to present KT-621 data at dermatology and lung conferences
-
-
-
-
-
-
-
Gilead exercises option for Kymera's cancer drug candidate KT-200
-
-
-
-
-
-
-
Stifel on Kymera Therapeutics (KYMR): 'pipeline progress remains an underappreciated long-term drive'
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) PT Raised to $110 at Stephens
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) PT Raised to $118 at Leerink Partners
-
-
-
-
-
-
-
Where can biotech stocks go from here? RBC answers
-
456,990 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

